Characteristics of all psoriasis arthritis patients and for men and women separately
| Total (n=131) | Men (n=66) 50.4% | Women (n=65) 49.6% | P value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years, mean (SD) | 51.9 (10.1) | 51.4 (10.2) | 52.5 (10.2) | 0.55 |
| BMI, kg/m2 (n=129), mean (SD) | 28.2 (4.4) | 28.6 (3.9) | 27.9 (4.9) | 0.36 |
| Currently smoking, n (%) | 21 (16.0%) | 9 (13.6%) | 12 (18.5%) | 0.45 |
| Living together (n=129), number (%) | 103 (79.8%) | 54 (83.1%) | 49 (76.6%) | 0.36 |
| Part- time/full time employed/working (n=130), number (%) | 74 (56.9%) | 44 (67.7%) | 30 (46.2%) | 0.013 |
| Musculoskeletal disease measures | ||||
| PsA disease duration, years, mean (SD) | 8.6 (6.6) | 8.4 (7.0) | 8.8 (6.1) | 0.73 |
| CRP, mg/L, mean (SD) | 4.8 (8.5) | 6.5 (10.8) | 3.0 (4.4) | 0.017 |
| TJC68 (n=130), mean (SD) | 10.4 (11.1) | 8.1 (10.3) | 12.7 (11.6) | 0.018 |
| SJC66 (n=130), mean (SD) | 0.6 (1.1) | 0.6 (1.1) | 0.7 (1.0) | 0.49 |
| DAPSA, range 0–164, mean (SD) | 18.6 (14.3) | 15.3 (13.0) | 21.9 (14.8) | 0.007 |
| PASDAS, mean (SD) | 3.1 (0.4) | 3.0 (0.5) | 3.2 (0.4) | 0.031 |
| MASES, range 0–13, mean (SD) | 2.9 (3.1) | 1.8 (2.4) | 4.1 (3.3) | <0.001 |
| IGA, VAS 0–100 mm, mean (SD) | 14.6 (12.5) | 14.5 (13.0) | 14.8 (12.1) | 0.89 |
| PROs | ||||
| PGA, VAS 0–100 mm, mean (SD) | 36.4 (24.8) | 30.8 (22.9) | 42.1 (25.5) | 0.009 |
| Pain, VAS 0–100 mm, mean (SD) | 33.9 (23.3) | 29.2 (22.3) | 38.7 (23.4) | 0.019 |
| Fatigue, VAS 0–100 mm, mean (SD) | 45.5 (32.7) | 35.6 (30.8) | 55.5 (31.7) | <0.001 |
| Morning stiffness, hour, mean (SD) | 0.95 (1.24) | 0.92 (1.31) | 0.97 (1.18) | 0.83 |
| Sleep disturbance†, NRS 0–10, mean (SD) | 3.34 (2.94) | 2.67 (2.70) | 4.03 (3.03) | 0.007 |
| Anxiety/depression, range 1–3, (n=127) mean (SD) | 1.43 (0.60) | 1.33 (0.54) | 1.52 (0.64) | 0.065 |
| MHAQ, range 0–3, mean (SD) | 0.42 (0.40) | 0.34 (0.33) | 0.51 (0.45) | 0.012 |
| Exercise ≥1 time per week, number (%) | 58 (44.3%) | 29 (43.9%) | 29 (44.6%) | 0.94 |
| Ultrasound | ||||
| Power Doppler signal present in any joints, entheses or tendons number (%) | 65 (49.6%) | 31 (47.0%) | 34 (52.3%) | 0.54 |
| PD sum score in joints, entheses and tendons (range 0–347), mean (SD) | 1.3 (1.9) | 1.3 (2.1) | 1.2 (1.7) | 0.90 |
| Comorbidity | ||||
| Comorbidities (n=128), (range 0–8), mean (SD) | 0.73 (0.96) | 0.48 (0.76) | 0.97 (1.08) | 0.004 |
| Comorbidities ≥1 (n=128), number (%) | 61 (47.7%) | 23 (35.9%) | 38 (59.4%) | 0.008 |
| Skin | ||||
| PASI (range 0–72) (n=130), mean (SD) | 2.5 (3.7) | 3.2 (4.2) | 1.8 (2.9) | 0.033 |
| PASI score ≥10 (n=130), number (%) | 10 (7.7%) | 8 (12.1%) | 2 (3.1%) | 0.054 |
| HRQoL measures | ||||
| 15D score (range 0–1), mean (SD) | 0.84 (0.10) | 0.86 (0.16) | 0.82 (0.18) | 0.008 |
| DLQI, range 0–30 (n=129), mean (SD) | 3.3 (3.6) | 3.2 (3.5) | 3.4 (3.8) | 0.72 |
| Treatment | ||||
| Current bDMARD, n (%) | 46 (35.1%) | 29 (43.9%) | 17 (26.2%) | 0.033 |
| Current csDMARD, n (%) | 78 (59.5%) | 42 (63.6%) | 36 (55.4%) | 0.34 |
| Ever bDMARD, n (%) | 51 (38.9%) | 30 (45.5%) | 21 (32.3%) | 0.12 |
| Ever csDMARD, n (%) | 117 (89.3%) | 59 (89.4%) | 58 (89.2%) | 0.98 |
Continuous variables are expressed as mean (standard variation); categorical variables are expressed as numbers (proportions). In the group comparisons, the independent sample t-test was used for continuous variables and the χ² test for categorical variables. The number of patients in the analyses is 131 if not otherwise indicated.
†The sleep question is phrased as follows: ‘Select the number that best describes the sleep difficulties (ie, resting at night) you felt due to your arthritis during the last week (from 0 (no difficulty) to 10 (extreme difficulty))’.
bDMARDs, biologic disease-modifying anti-rheumatic drugs; BMI, body mass index; CRP, C reactive protein; csDMARDs, conventional synthetic DMARDs; DAPSA, Disease Activity Index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; ESR, erythrocyte sedimentation rate; IGA, Investigator Global Assessment; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MHAQ, Modified Health Assessment Questionnaire; NRS, Numeric Rating Scale; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area Severity Index; PGA, patient global assessment; PROs, patient-reported outcome measures; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.